Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.
Nathan Bahary, MD, PhD, an associate professor at the University of Pittsburgh School of Medicine, as well as a medical oncologist and hematologist at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the benefits of ivosidenib (Tibsovo) in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.
IDH1 mutations are known to occur in 10% to 13% of patients with intrahepatic cholangiocarcinoma, according to Bahary.
Ivosidenib (Tibsovo) is 1 agent that is currently approved by the FDA for use in patients with IDH1-mutated acute myeloid leukemia. Another study examined the agent in patients with IDH1-mutated cholangiocarcinoma. Ivosidenib was found to improve progression-free survival and elicit durable responses in this population. Notably, this trial permitted crossover; thus, no confirmed overall survival benefit was noted, but benefit is possible given the extent of the mutations and the durability of responses to treatment, Bahary concludes.